Similarly, dual CAR-NKs targeting prostate cancer cells that express both the prostate-specific membrane antigen (PSMA) and the prostate stem cell antigen (PSCA), show that this is a promising approach for solid tumours [203]. This evidence concerns the gene FOLH1 and prostate carcinoma.